Adalimumab biosimilar launched in Japan

Biosimilars/News | Posted 03/12/2021 comments 0
Adalimumab 2 V14A10

Japan-based Mochida Pharmaceutical (Mochida) announced on 25 November 2021 that its adalimumab biosimilar had been launched in Japan following the listing of the drug on the National Health Insuran...

More >
LATIN AMERICAN FORUM MOST READ
25 AA011049
YLB113 etanercept biosimilar autoinjector 'safe and effective’
Posted 05/11/2021

Analysis of the YLB113 etanercept autoinjector, a biosimilar to reference etanercept, f...

AA010962
Regulation of the registration of biological drugs in Latin America
Posted 19/11/2021

Biological drugs are defined as products with active ingredients produced from a biolog...

ANAMED V21K19LT
Biosimilars approved in Chile
Posted 19/11/2021

In Chile, the regulatory body responsible for the approval of biological medicines is t...

Home/Non‐Biological Complex Drugs
Liposome V15L11

On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft guidance...

More >

Generics

FDA closes Zhejiang Huahai Pharmaceutical warning letter
Generics/General | Posted 19/11/2021
Pfizer and Merck COVID-19 antiviral progress
Generics/News | Posted 12/11/2021
FDA reaches 100 generic approvals
Generics/General | Posted 12/11/2021
Call for drug pricing transparency
Generics/Research | Posted 05/11/2021

Biosimilars

Adalimumab biosimilar launched in Japan
Biosimilars/News | Posted 03/12/2021
Evidence on automatic substitution of biologicals is limited
Biosimilars/Research | Posted 03/12/2021
Definition of biological terms in Latin America
Biosimilars/Research | Posted 03/12/2021